{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:53:01Z","timestamp":1781153581358,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-03949-3","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T17:02:03Z","timestamp":1720112523000},"page":"342-348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune checkpoint inhibitor-associated new-onset hypophysitis: a retrospective analysis using the FAERS"],"prefix":"10.1007","volume":"86","author":[{"given":"Difei","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geheng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"issue":"17","key":"3949_CR1","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"J.R. Brahmer, C. Lacchetti, B.J. Schneider et al. National Comprehensive Cancer Network Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 36(17), 1714\u20131768 (2018)","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"3949_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"R. Barroso-Sousa, W.T. Barry, A.C. Garrido-Castro et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 4(2), 173\u2013182 (2018)","journal-title":"JAMA Oncol."},{"key":"3949_CR3","doi-asserted-by":"publisher","first-page":"9551","DOI":"10.2147\/CMAR.S224791","volume":"12","author":"M Tsoli","year":"2020","unstructured":"M. Tsoli, G. Kaltsas, A. Angelousi et al. Managing ipilimumab-induced hypophysitis: challenges and current therapeutic strategies. Cancer Manag. Res. 12, 9551\u20139561 (2020)","journal-title":"Cancer Manag. Res."},{"key":"3949_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"L.S. Chang, R. Barroso-Sousa, S.M. Tolaney et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr. Rev. 40, 17\u201365 (2019)","journal-title":"Endocr. Rev."},{"issue":"4","key":"3949_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","volume":"29","author":"AC Maker","year":"2006","unstructured":"A.C. Maker, J.C. Yang, R.M. Sherry et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J. Immunother. 29(4), 455\u2013463 (2006)","journal-title":"J. Immunother."},{"issue":"25","key":"3949_CR6","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","volume":"23","author":"P Attia","year":"2005","unstructured":"P. Attia, G.Q. Phan, A.V. Maker et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23(25), 6043\u20136053 (2005)","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"3949_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2217\/imt-2016-0147","volume":"9","author":"YH Shang","year":"2017","unstructured":"Y.H. Shang, Y. Zhang, J.H. Li et al. Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis. Immunotherapy 9(3), 261\u2013272 (2017)","journal-title":"Immunotherapy"},{"issue":"11","key":"3949_CR8","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"A.T. Faje, R. Sullivan, D. Lawrence et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J. Clin. Endocrinol. Metab. 99(11), 4078\u20134085 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"3949_CR9","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1210\/clinem\/dgac161","volume":"107","author":"A Labadzhyan","year":"2022","unstructured":"A. Labadzhyan, K. Wentzel, O. Hamid et al. Endocrine autoantibodies determine immune checkpoint inhibitor-induced endocrinopathy: A prospective study. J. Clin. Endocrinol. Metab. 107(7), 1976\u20131982 (2022)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"3949_CR10","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","volume":"186","author":"P Caturegli","year":"2016","unstructured":"P. Caturegli, G.D. Dalmazi, M. Lombardi et al. Hypophysitis secondary to cytotoxic T- lymphocyte associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am. J. Pathol. 186(12), 3225\u20133235 (2016)","journal-title":"Am. J. Pathol."},{"key":"3949_CR11","doi-asserted-by":"publisher","first-page":"22246","DOI":"10.1073\/pnas.1908079116","volume":"116","author":"SA Tahir","year":"2019","unstructured":"S.A. Tahir, J. Gao, Y. Miura et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc. Natl. Acad. Sci. USA 116, 22246\u201322251 (2019)","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"3949_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101370","volume":"34","author":"G Elia","year":"2020","unstructured":"G. Elia, S.M. Ferrari, M.R. Galdiero et al. New insights in endocrine-related adverse events associated to immune checkpoint blockade. Best. Pr. Res Clin. Endocrinol. Metab. 34(1), 101370 (2020)","journal-title":"Best. Pr. Res Clin. Endocrinol. Metab."},{"issue":"16","key":"3949_CR13","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.3390\/cancers13164036","volume":"13","author":"G Bellastella","year":"2021","unstructured":"G. Bellastella, C. Carbone, L. Scappaticcio et al. Hypothalamic-pituitary autoimmunity in patients treated with anti-PD-1 and anti-PD-L1 antibodies. Cancers (Basel) 13(16), 4036 (2021)","journal-title":"Cancers (Basel)"},{"key":"3949_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002493","volume":"9","author":"T Kobayashi","year":"2021","unstructured":"T. Kobayashi, S. Iwama, D. Sugiyama et al. Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors. J. Immunother. Cancer 9, e00249 (2021)","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"3949_CR15","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3390\/jpm11101026","volume":"11","author":"S Chiloiro","year":"2021","unstructured":"S. Chiloiro, F. Russo, T. Tartaglione et al. Molecular and genetic immune biomarkers of primary and immune-therapy induced hypophysitis: From laboratories to the clinical practice. J. Pers. Med. 11(10), 1026 (2021)","journal-title":"J. Pers. Med."},{"issue":"8","key":"3949_CR16","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/jpm13081210","volume":"13","author":"S Menotti","year":"2023","unstructured":"S. Menotti, A. Giampietro, S. Raia et al. Unveiling the etiopathogenic spectrum of hypophysitis: A narrative review. J. Pers. Med. 13(8), 1210 (2023)","journal-title":"J. Pers. Med"},{"issue":"3","key":"3949_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4158\/EP11273.OR","volume":"18","author":"L Min","year":"2012","unstructured":"L. Min, A. Vaidya, C. Becker, Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: A case series. Endocr. Pract. 18(3), 351\u2013355 (2012)","journal-title":"Endocr. Pract."},{"key":"3949_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2018.09.016","volume":"104","author":"N Tshuma","year":"2018","unstructured":"N. Tshuma, N. Glynn, J. Evanson et al. Hypothalamitis and severe hypothalamic dysfunction associated with anti-programmed cell death ligand 1 antibody treatment. Eur. J. Cancer 104, 247\u2013249 (2018)","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"3949_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1507\/endocrj.EJ23-0050","volume":"70","author":"Y Takahashi","year":"2023","unstructured":"Y. Takahashi, Paraneoplastic autoimmune hypophysitis: a novel form of paraneoplastic endocrine syndrome. Endocr. J. 70(6), 559\u2013565 (2023)","journal-title":"Endocr. J."},{"issue":"1","key":"3949_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5701-6","volume":"19","author":"X Sun","year":"2019","unstructured":"X. Sun, R. Roudi, T. Dai et al. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer 19(1), 558 (2019)","journal-title":"BMC Cancer"},{"issue":"14","key":"3949_CR21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"J.D. Wolchok, C. Chiarion-Sileni, R. Gonzalez et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med 377(14), 1345\u20131356 (2017)","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"3949_CR22","doi-asserted-by":"publisher","first-page":"3201611","DOI":"10.1001\/jamanetworkopen.2020.1611","volume":"3","author":"CY Chang","year":"2020","unstructured":"C.Y. Chang, H. Park, D.C. Malone et al. Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: A systematic review and network meta-analysis. JAMA Netw. Open 3(3), 3201611 (2020)","journal-title":"JAMA Netw. Open"},{"issue":"5","key":"3949_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","volume":"30","author":"B Escudier","year":"2019","unstructured":"B. Escudier, C. Porta, M. Schmidinger et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30(5), 706\u2013702 (2019)","journal-title":"Ann. Oncol."},{"issue":"1","key":"3949_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56025-6","volume":"9","author":"FZ Wu","year":"2019","unstructured":"F.Z. Wu, P.L. Kuo, Y.L. Huang et al. Differences in lung cancer characteristics and mortality rate between screened and non-screened cohorts. Sci. Rep. 9(1), 19386 (2019). 18","journal-title":"Sci. Rep."},{"issue":"3","key":"3949_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/CMR.0000000000000526","volume":"29","author":"MA Wilson","year":"2019","unstructured":"M.A. Wilson, J. Zhong, B. Rosenbaum et al. Impact of initial stage on metastatic melanoma survival. Melanoma Res. 29(3), 281\u2013288 (2019)","journal-title":"Melanoma Res"},{"issue":"1","key":"3949_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/ijc.33744","volume":"150","author":"N Zaorsky","year":"2022","unstructured":"N. Zaorsky, X. Wang, S.M. Garrett et al. Pan-cancer analysis of prognostic metastatic phenotypes. Int J. Cancer 150(1), 132\u2013141 (2022)","journal-title":"Int J. Cancer"},{"key":"3949_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"J.C. Osorio, A. Ni, J.E. Chaft et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann. Oncol. 28, 583\u2013589 (2017)","journal-title":"Ann. Oncol."},{"key":"3949_CR28","first-page":"e1375642","volume":"19","author":"HI Kim","year":"2017","unstructured":"H.I. Kim, M. Kim, S.H. Lee et al. Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. Onco Immunol. 19, e1375642 (2017)","journal-title":"Onco Immunol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03949-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03949-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03949-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T05:39:34Z","timestamp":1727761174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03949-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3949"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03949-3","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"29 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All cases in the study were anonymous and all data was available in public resource, and this study was waived from informed consent and ethics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}